Jason Kelly (Photographer: Kyle Grillot/Bloomberg via Getty Images)

Gink­go nabs $DNA, biotech's most sought af­ter tick­er, for free in sweet­en­er from NYSE

When Gink­go went com­par­i­son shop­ping for a fi­nan­cial mar­ket to list their now $15 bil­lion com­pa­ny, the New York Stock Ex­change had a back-pock­et sweet­en­er the Nas­daq couldn’t of­fer: The most sought-af­ter tick­er in biotech, $DNA.

DNA — the most fa­mous three let­ters in bi­ol­o­gy and the tick­er for the world’s first biotech, Genen­tech, from 1999 un­til it was bought out by Roche for $48 bil­lion in 2009 — will now be the tick­er for Gink­go, a 12-year-old syn­thet­ic bi­ol­o­gy start­up with grand am­bi­tions to change not on­ly how drugs, but al­so every­day prod­ucts like meat and per­fumes, are made.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.